Ultragenyx Pharmaceutical (NASDAQ:RARE) Director Shehnaaz Suliman Sells 5,740 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares in the company, valued at approximately $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ultragenyx Pharmaceutical Stock Down 3.2%

RARE stock opened at $24.19 on Tuesday. The business’s 50-day moving average price is $23.14 and its 200-day moving average price is $26.38. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $42.37. The stock has a market cap of $2.38 billion, a P/E ratio of -3.96 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. During the same period in the prior year, the firm posted ($1.57) earnings per share. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on RARE. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. HC Wainwright lowered their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. The Goldman Sachs Group cut Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Morgan Stanley lifted their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Finally, Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $60.41.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of the stock. Covestor Ltd increased its position in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the last quarter. Huntington National Bank increased its position in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the last quarter. Xponance Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.1% during the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 406 shares during the last quarter. Amalgamated Bank increased its position in shares of Ultragenyx Pharmaceutical by 6.9% during the 3rd quarter. Amalgamated Bank now owns 7,226 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 469 shares during the last quarter. Finally, Arizona State Retirement System increased its position in shares of Ultragenyx Pharmaceutical by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 25,176 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 533 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.